Last reviewed · How we verify
Fluticasone Furoate Nasal Spray
Fluticasone furoate is a corticosteroid that binds to glucocorticoid receptors in nasal tissue to reduce inflammation and allergic responses.
Fluticasone furoate is a corticosteroid that binds to glucocorticoid receptors in nasal tissue to reduce inflammation and allergic responses. Used for Allergic rhinitis, Non-allergic rhinitis, Nasal polyps (in some markets).
At a glance
| Generic name | Fluticasone Furoate Nasal Spray |
|---|---|
| Also known as | GW685698, Veramyst, Flonase® is a registered trademark of GlaxoSmithKline |
| Sponsor | GlaxoSmithKline |
| Drug class | Intranasal corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
As a selective glucocorticoid receptor agonist, fluticasone furoate suppresses inflammatory cytokine production, reduces immune cell infiltration, and decreases mucus secretion in the nasal mucosa. This leads to reduced nasal congestion, sneezing, and rhinorrhea associated with allergic and non-allergic rhinitis. The intranasal formulation provides local anti-inflammatory effects with minimal systemic absorption.
Approved indications
- Allergic rhinitis
- Non-allergic rhinitis
- Nasal polyps (in some markets)
Common side effects
- Headache
- Epistaxis (nosebleed)
- Nasal irritation
- Pharyngitis
- Dysgeusia (altered taste)
Key clinical trials
- Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps (PHASE3)
- Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) (PHASE2)
- INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION (PHASE4)
- A Prospective, Randomized, Controlled Study Comparing the Efficacy of Intranasal Corticosteroids (INCS) Combined With Intranasal Antihistamines (INAH) and INCS Combined With Oral Antihistamines (OAH) in the Treatment of Moderate to Severe Allergic Rhinitis Symptoms (PHASE4)
- As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis (PHASE3)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
- Budesonide Nasal Irrigation Versus Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis Patients (PHASE4)
- Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Furoate Nasal Spray CI brief — competitive landscape report
- Fluticasone Furoate Nasal Spray updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI